FDA Approves Afrezza for Children 6 and Older, First Rapid-Acting Inhaled Insulin
The US Food and Drug Administration approved Afrezza for children aged 6 years and older with diabetes, making it the first rapid-acting inhaled insulin approved for pediatric patients.
The decision adds an inhaled option to pediatric diabetes care. MannKind said the approval is the first needle-free treatment option for pediatric patients living with type 1 diabetes.
From the sources (3 posts)
@polymarketNEW: FDA approves inhaled insulin for children.
@contemppedsA new option is now available for pediatric diabetes care. The FDA has approved Afrezza, the first rapid-acting inhaled insulin for children aged 6 years and older with diabetes.
@mannkindcorpMannKind is excited to announce that the U.S. Food and Drug Administration (FDA) has approved the first needle-free treatment option for pediatric patients living with type 1 diabetes. Learn more in the Company Announcement here: https://t.